The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials

Publication date: May 2018
Source:European Journal of Cancer, Volume 95
Author(s): Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, Stan B. Kaye, Udai Banerji, Juanita S. Lopez, Johann de Bono, Winette T.A. van der Graaf, Angela J. George
IntroductionAdolescents and young adults (AYAs) diagnosed with cancer between ages 15–39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals.AimConsidering AYAs with advanced solid tumours managed in a specialist drug development unit (DDU), the aims of this study were to investigate the use and impact of:1. Germline genetic assessment.2. Tumour molecular profiling.MethodsAYAs treated in the DDU at the Royal Marsden Hospital between 2002 and 2016 were identified from departmental databases. Data regarding clinicopathological features, clinical assessments and germline and tumour genetic testing were retrieved by chart review.ResultsThe study cohort included 219 AYAs. Common cancer types included sarcoma (41, 19%); cervical (27, 12%); breast (25, 11%); ovarian (23, 11%) and colorectal (21, 10%) cancers. Germline testing was undertaken in 34 (16%) patients, 22 of whom carried a pathogenic variant. Using current testing criteria, an additional 32 (15%) would be eligible for germline testing based on their personal history of cancer alone. Tumour testing was undertaken in 46 (21%) individuals. Somatic mutations were commonly identified in TP53 13 (28%); PIK3CA (8, 18%); KRAS (4, 9%) and MET 5 (11%).DiscussionA significant proportion of AYAs with advanced cancer have targetable somatic or germline mutations. Consideration of familial risk factors and inclusion of germline testing wherever appropriate can complement tumour testing to optimise patient management and inform management of at-risk relatives.



https://ift.tt/2GpA7YI